The SSRI Family

## Overview

Selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed antidepressants, also used in anxiety disorders, OCD, PTSD, and premenstrual dysphoric disorder. They selectively block the serotonin transporter (SERT, SLC6A4), preventing synaptic reuptake of serotonin (5-HT) and increasing its concentration in the synapse. Despite their chemical diversity, all SSRIs share a unifying pharmacophore: a basic amine linked through a spacer to an aryl group that engages SERT's central binding site.

## Binding Mode at SERT

X-ray structures of SERT (and the homologous bacterial transporter LeuT) reveal that SSRIs bind in the central S1 pocket, which accommodates the endogenous substrate 5-HT. The protonated amine makes a salt bridge with Asp98 in TM1. The aryl moiety nestles in a hydrophobic cleft formed by Tyr95, Phe335, and Ile172. Halogen substituents on the aryl extend into a sub-pocket formed by Thr439 and Ser336, providing additional van der Waals contacts and stabilizing the outward-occluded conformation that locks the transporter in an inactive state.

## Structural Diversity of SSRIs

Despite sharing the same mechanism, approved SSRIs are structurally distinct:

- **Fluoxetine**: Phenylpropanolamine skeleton with 4-trifluoromethylphenoxy group; the CF3 is critical for potency and selectivity; long half-life (~6 days) due to norfluoxetine metabolite
- **Paroxetine**: Piperidyl benzodioxol; most potent SSRI at SERT (Ki ~0.08 nM); also inhibits muscarinic, histaminic, and adrenergic receptors, contributing to its side effect profile
- **Sertraline**: 1,2,3,4-Tetrahydro-naphthalenamine with *trans*-3,4-dichlorophenyl; the (1S,4S)-isomer is 200x more potent than (1R,4R); minimal off-target activity
- **Citalopram/escitalopram**: Bicyclic phthalane (isobenzofuran) core; citalopram is a racemate; the (S)-enantiomer (escitalopram) accounts for essentially all SERT activity; the (R)-enantiomer may occupy an allosteric site that slightly reduces efficacy
- **Fluvoxamine**: Arylalkyl oxime ether; unique structure among SSRIs; also a potent sigma-1 receptor agonist, which may contribute to anxiolytic effects

## Selectivity Over NET and DAT

SERT selectivity over the norepinephrine transporter (NET) and dopamine transporter (DAT) is achieved by steric and electronic differences. SERT's binding pocket is slightly smaller and more hydrophobic than NET's. The bulky CF3 (fluoxetine) and gem-dichlorophenyl (sertraline) substituents clash sterically with NET residues. Paroxetine's methylenedioxyphenyl achieves SERT selectivity partly through the conformational constraint of the piperidine ring, which is less optimal for NET geometry.

## Stereochemistry

Several SSRIs are chiral. For sertraline, the (1S,4S) configuration is ~200-fold more potent than the enantiomer. For citalopram, escitalopram (S-enantiomer) is the eutomer; the R-enantiomer is inactive or weakly antagonistic at an allosteric site. Paroxetine has a trans-configured piperidine ring; the cis-isomer has significantly reduced potency.

## Metabolism and Drug Interactions

SSRIs are primarily metabolized by CYP2D6 (fluoxetine, paroxetine) or CYP2C19 (citalopram, escitalopram). Fluoxetine and paroxetine are potent CYP2D6 inhibitors, causing clinically significant drug interactions. Sertraline undergoes moderate CYP2D6 inhibition. Fluvoxamine inhibits CYP1A2 and CYP2C19. Escitalopram and sertraline have the cleanest interaction profiles.

## Key Takeaways

- All SSRIs share a basic amine pharmacophore for SERT Asp98 interaction and an aryl group for the hydrophobic S1 pocket
- Halogen substitution (F, Cl, CF3) on the aryl ring increases potency and metabolic stability
- Stereochemistry is critical: active enantiomers are typically 100-200x more potent than distomers
- Structural diversity drives differential selectivity, PK, and off-target profiles within the class
- Paroxetine achieves highest SERT potency; sertraline and escitalopram have the cleanest selectivity profiles